Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 1
2022 1
2023 0

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
Dou KX, Tan MS, Tan CC, Cao XP, Hou XH, Guo QH, Tan L, Mok V, Yu JT. Dou KX, et al. Alzheimers Res Ther. 2018 Dec 27;10(1):126. doi: 10.1186/s13195-018-0457-9. Alzheimers Res Ther. 2018. PMID: 30591071 Free PMC article.
BACKGROUND: Cholinesterase inhibitors and memantine have been approved for management of Alzheimer's disease (AD), but there has been no consensus about the choice of various types and doses of drugs at different stages. ...METHODS: We se …
BACKGROUND: Cholinesterase inhibitors and memantine have been approved for management of Alzheimer's d …
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Veroniki AA, Ashoor HM, Rios P, Seitidis G, Stewart L, Clarke M, Tudur-Smith C, Mavridis D, Hemmelgarn BR, Holroyd-Leduc J, Straus SE, Tricco AC. Veroniki AA, et al. BMJ Open. 2022 Apr 26;12(4):e053012. doi: 10.1136/bmjopen-2021-053012. BMJ Open. 2022. PMID: 35473731 Free PMC article.
OBJECTIVE: To examine the comparative efficacy and safety of cognitive enhancers by patient characteristics for managing Alzheimer's dementia (AD). ...We appraised study quality with the Cochrane risk-of-bias. We conducted a two-stage random-effects …
OBJECTIVE: To examine the comparative efficacy and safety of cognitive enhancers by patient characteristics for managing Al …
Comparative efficacy and safety of cognitive enhancers for treating vascular cognitive impairment: systematic review and Bayesian network meta-analysis.
Jin BR, Liu HY. Jin BR, et al. Neural Regen Res. 2019 May;14(5):805-816. doi: 10.4103/1673-5374.249228. Neural Regen Res. 2019. PMID: 30688266 Free PMC article.
DATA SELECTION: Randomized controlled trials on donepezil, galantamine, rivastigmine, and memantine as monotherapy in the treatment of vascular cognitive impairment were included. A Bayesian network meta-analysis was conducted. OUT …
DATA SELECTION: Randomized controlled trials on donepezil, galantamine, rivastigmine, and memantine as monothera …